雖然這篇elafibranor鄉民發文沒有被收入到精華區：在elafibranor這個話題中，我們另外找到其它相關的精選爆讚文章
[爆卦]elafibranor是什麼？優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
#1Genfit NASH藥物三期試驗失敗股價狂跌65% - 環球生技
Elafibranor 是Genfit的主力產品，為口服藥物，透過活化PPARα和PPARδ兩條途徑來治療NASH，PPARα和PPARδ與多種生理過程有關，包括脂肪代謝、葡萄糖代謝平衡 ...
-
#2Elafibranor - Wikipedia
Elafibranor is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, ...
-
#3Elafibranor: a potential drug for the treatment of ... - PubMed
由 MJW Van Meeteren 著作 · 2020 · 被引用 35 次 — Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and insulin metabolism, two key components in pathophysiology of ...
-
#44) Elafibranor | FierceBiotech
But though Genfit abandoned the study, it hasn't completely given up on the drug. It's pushing ahead with elafibranor in primary biliary ...
-
#5Elafibranor | ≥99%(HPLC) | Selleck | PPAR agonist
Elafibranor ; Description, Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator- ...
-
#6Elafibranor, an Agonist of the Peroxisome ... - Science Direct
由 V Ratziu 著作 · 2016 · 被引用 794 次 — Elafibranor is an agonist of the peroxisome proliferator−activated receptor-α and peroxisome proliferator−activated receptor-δ.
-
#7CLINICAL—LIVER - Elafibranor, an Agonist of the Peroxisome ...
Elafibranor (GFT505) is a dual PPARa/d agonist that has demonstrated efficacy in disease models of nonalcoholic fatty liver disease (NAFLD)/NASH and liver ...
-
#8Phase 3 Study to Evaluate the Efficacy and Safety of ...
To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) subjects with fibrosis by assessing the ...
-
#9Elafibranor for the treatment of NAFLD: One pill, two ... - Elsevier
Elafribranor, also known as GFT505, is a drug compound designed to target peroxisome proliferator-activated receptors (PPARs), more specifically elafibranor is ...
-
#10Elafibranor (GFT505, CAS Number: 923978-27-2) - Cayman ...
Elafibranor is an agonist of the peroxisome proliferator-activated receptors (PPAR) α and δ. It increases HDL secretion and expression of the lipid-related ...
-
#11GENFIT Scraps Elafibranor in NASH, Sets New Strategic Focus
France's GENFIT will discontinue the Phase III RESOLVE-IT study of elafibranor in this indication. Why they are shutting it down?
-
#12Elafibranor (GFT505) | PPARα/δ Agonist | MedChemExpress
Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. For research use only. We do not sell to patients. Elafibranor Chemical ...
-
#13Beneficial effects of elafibranor on NASH in E3L ... - Nature
Elafibranor is a dual agonist acting upon the peroxisome proliferator-activated receptors (PPARs) α and δ, nuclear receptors that play a key ...
-
#14Elafibranor | ≥99%(HPLC) | PPAR agonist | AdooQ®
Elafibranor is an agonist of the peroxisome proliferator-activated Receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis ...
-
#15elafibranor | Ligand page - IUPHAR/BPS Guide to ...
Comment: Elafibranor (GFT-505) is a PPARα/δ agonist. It was taken into clinical development by Genfit, as a therapuetic for nonalcoholic steatohepatitis ...
-
#16Elafibranor in PBC | Genfit
Elafibranor was granted Breakthrough Therapy designation by the FDA in April 2019 for the treatment of PBC in adults with inadequate response to UDCA, as well ...
-
#17Elafibranor | PPAR 抑制剂| 现货供应| 美国品牌
Elafibranor (GFT505) 是PPAR-alpha和PPAR-δ的激动剂，改善胰岛素敏感度、有益于葡萄糖稳态、脂质代谢并减少炎症。
-
#18Genfit rises from the ashes of elafibranor | Evaluate
The deal validates Genfit's decision to press on with elafibranor in the new indication, primary biliary cholangitis (PBC), where the project's ...
-
#19Elafibranor, an Agonist of the Peroxisome ... - Europe PMC
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis ...
-
#20(E)-Elafibranor | C22H24O4S | ChemSpider
(E)-Elafibranor. 2-(2,6-Dimethyl-4-{(1E)-3-[4-(methylsulfanyl)phenyl]-3-oxo-1-propen-1-yl}phenoxy)-2-methylpropanoic acid [ACD/IUPAC Name].
-
#21Elafibranor in Primary Biliary Cholangitis | Cedars-Sinai
Elafibranor in Primary Biliary Cholangitis study focuses on individuals who have been diagnosed with primary biliary cholangitis (PBC), a chronic liver ...
-
#22Ipsen and GENFIT enter into exclusive licensing agreement ...
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part ...
-
#23Elafibranor - Genfit - AdisInsight
PPAR plays a central role in the regulation of lipid metabolism and control of glycaemia. Elafibranor acts on two subtypes of PPAR (α, δ), with preferential ...
-
#24Elafibranor: a potential drug for the treatment of nonalcoholic ...
Introduction: Nonalcoholic fatty liver disease (NAFLD) encompasses a progressive disease phenotype starting from simple steatosis, which can progress to ...
-
#25Genfit abandons late-stage trial of NASH drug elafibranor -
2020年7月23日 — France's Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve patient outcomes ...
-
#26A randomized placebo-controlled trial of elafibranor in patients ...
Elafibranor was generally well-tolerated over the duration of treatment. Background & Aims. Patients with primary biliary cholangitis (PBC) who ...
-
#27(GFT505) NASH Treatment - GOLDEN 505 Study & Commentary
Elafibranor, (GFT505), an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without ...
-
#28New Clinical Data on GENFIT's Investigational Compound
It was granted a Breakthrough Therapy designation by the FDA in this indication. Elafibranor is an investigational compound that has not been ...
-
#29EMEA-001857-PIP02-20 | European Medicines Agency
Active substance. Elafibranor ; Therapeutic area. Gastroentology-Hepatology ; Decision number. P/0295/2020 ; PIP number. EMEA-001857-PIP02-20.
-
#30Elafibranor - Orphanet
Elafibranor · INN (International Nonproprietary Name) : elafibranor · Code name : - · Chemical name or description : 2-(2,6-dimethyl-4-{3-[4-(methylsulfanyl)phenyl ...
-
#31RESOLVE-IT: A Study of Elafibranor in Patients with NASH ...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic ...
-
#32Clinical Trials - Mayo Foundation for Medical Education and ...
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause ...
-
#33Elafibranor | 923978-27-2 | Biosynth Carbosynth
Buy high quality Elafibranor 923978-27-2 from Biosynth Carbosynth. ... Elafibranor. Dual agonist of PPARα and PPARδ receptors.
-
#34ELAFIBRANOR - Inxight Drugs
Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. Elafibranor (GFT505) reverses nonalcoholic ...
-
#35Elafibranor | PPAR α/δ agonist | GFT505 | GFT 505 - Axon ...
Axon ID Name From price 1227 WY 14643 €45.00 1237 GW 7647 €95.00 1567 KRP 297 €95.00
-
#36(PDF) Elafibranor, an Agonist of the Peroxisome Proliferator ...
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis ...
-
#37Search for elafibranor - EU Clinical Trials Register
Full Title: A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) treatment administered once ...
-
#38Elafibranor - PPAR - TargetMol
Elafibranor is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.
-
#39Elafibranor Effect Not Significantly Different From Placebo in ...
GENFIT announced that the phase 3 RESOLVE-IT trial of elafibranor in patients with nonalcoholic steatohepatitis (NASH) and fibrosis did not ...
-
#40Both Elafibranor and Liraglutide Improve NAFLD / NASH but ...
Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and ...
-
#41Elafibranor | Abbexa Ltd
Elafibranor is a small molecule which can act as a PPARalpha/delta agonist. This product acts on the following target types: Transcription factor.
-
#42While we wait for NASH data, Genfit reports positive ...
The 12-week phase II trial tested two doses of the dual PPARα/δ agonist elafibranor against a placebo in PBC patients that did not derive adequate benefit from ...
-
#43Elafibranor improves diet-induced nonalcoholic ...
Elafibranor improved NASH and heart failure in free choice fed hamsters. •. This NASH hamster model will be useful for validating novel drug ...
-
#44Elafibranor, inhibitor - MyBioSource
Elafibranor is an agonist of the peroxisome proliferator-activated Receptor-?? and -??, induces resolution of nonalcoholic steatohepatitis without fibrosis ...
-
#45Genfit rockets on signing two deals in one day, now with Ipsen ...
Genfit suffered a clinical trial setback with elafibranor last year, leading to the company dropping development of the drug in ...
-
#46WO2019099761A1 - Solid state forms of elafibranor - Google ...
Disclosed are solid state forms of Elafibranor and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
-
#47Study of Elafibranor in Patients With Primary Biliary ...
The main objective of the study is to evaluate the effect of daily oral administration of 80mg elafibranor on cholestasis (impairment of ...
-
#48Elafibranor in Patients With Primary Biliary Cholangitis and an ...
Alkaline phosphatase (ALP) was significantly reduced in both elafibranor dosing groups, which was in contrast to the increase in ALP in the ...
-
#49GENFIT Scraps Elafibranor in NASH, Sets New Strategic Focus
Elafibranor showed promising results in a Phase II clinical trial for PBC and was granted Breakthrough Therapy designation by the U.S. Food and ...
-
#50HY-16737-1ml | Elafibranor [923978-27-2] Quimigen
Elafibranor (GFT505) is being developed as a dual PPAR-α/PPAR-δ agonist for the treatment of T2DM and non-alcoholic fatty liver disease.
-
#51Selleck Chemical LLC Elafibranor 5mg 923978-27-2 GFT505
Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ). It ...
-
#52Elafibranor for the treatment of NAFLD: One pill ... - Medigraphic
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without ...
-
#53Ipsen and GENFIT Enter Into Exclusive Licensing Agreement
It was granted a Breakthrough Therapy designation by the FDA in this indication. Elafibranor is an investigational compound that has not been ...
-
#54Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 ...
Elafibranor is designed to bind to and activate PPAR alpha and PPAR delta, two receptors that control the expression of genes involved in ...
-
#55Beneficial effects of elafibranor on NASH ... - TNO Publications
This has raised questions on the adequacy of preclinical models. Elafibranor is one of the drugs currently in late stage development which had mixed results for ...
-
#56Elafibranor: a potential drug for the treatment of ... - X-MOL
... regulate lipid and insulin metabolism, two key components in pathophysiology of NAFLD and NASH. Elafibranor acts as an agonist of PPAR-α.
-
#57Metabolic and hepatic effects of liraglutide, obeticholic acid ...
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic ...
-
#58Figure 2 | Elafibranor Inhibits Chronic Kidney Disease ...
Chronic elafibranor treatments increased insulin sensitivity of HFD mice with steatohepatitis. Elafibranor had no effects on water ((a), mL/wk) and food ...
-
#59Elafibranor | BioWorld
Genfit SA's global development and commercialization deal with Ipsen Pharma SA for phase III-stage elafibranor in primary biliary cholangitis (PBC) – plus a ...
-
#60Elafibranor moves to Phase 3 Study called ELATIVE
The Phase 3 study will consist of Elafibranor 80mg for double blind period (52 to 104 weeks). After completion of the double blind period, ...
-
#61肝病疗法elafibranor获FDA突破性疗法认定即将进入3期临床
Elafibranor 是一款“first-in-class”PPARα/δ激动剂，在治疗PBC患者的2期临床试验中表现出积极疗效，它同时在3期临床试验中治疗非酒精性脂肪性 ...
-
#62Medline ® Abstract for Reference 42 of 'Pathogenesis of ...
Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor ...
-
#63GENFIT Announces FDA Grant of Breakthrough Therapy ...
FDA grants elafibranor Breakthrough Therapy Designation, based on Phase 2 data, for treatment of PBC (Primary Biliary Cholangitis) in adults ...
-
#64δ, Induces Resolution of Nonalcoholic Steatohepatitis Without ...
Background & Aims Elafibranor is an agonist of the peroxisome proliferator−activated receptor-α and peroxisome proliferator−activated receptor-δ.
-
#65Metabolic and hepatic effects of liraglutide, obeticholic acid
Elafibranor and OCA reduced histopathological scores of hepatic steatosis and inflammation in both models, but only elafibranor reduced fibrosis ...
-
#66Elafibranor restricts lipogenic and inflammatory responses in a ...
Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. Boeckmans J, Buyl K, Natale A, Vandenbempt V, ...
-
#67Elafibranor safe, effective in patients with PBC - Healio
Patients with primary biliary cholangitis treated with elafibranor experienced lowered alkaline phosphatase after 12 weeks, according to ...
-
#68Genfit's elafibranor trial expected to close enrolment next month
Genfit's 2000-patient trial investigating elafibranor in nonalcoholic steatohepatitis is likely to close enrolment sometime in September.
-
#69Elafibranor: Uses, Interactions, Mechanism of Action - DrugBank
Elafibranor (code name GFT505) is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight ...
-
#70dual-action elafibranor metformin salt for treating obesity ...
The present invention relates to drugs derived from elafibranor. It relates more specifically to a composition comprising at least one active ingredient, ...
-
#71Elafibranor supplier | CAS 923978-27-2 | Focus Biomolecules
Elafibranor (923978-27-2) is a dual PPARα/δ agonist (EC50 PPARα = 10-20 nM; PPARδ = 100-150 nM).
-
#72Elafibranor and liraglutide improve differentially liver ... - Gubra
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non- alcoholic steatohepatitis.
-
#73Elafibranor, Placebo - Register für klinische Studien - ICH GCP
Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von Elafibranor im Vergleich zu Placebo bei Patienten mit nichtalkoholischer Steatohepatitis ...
-
#74WO/2019/099761 SOLID STATE FORMS OF ELAFIBRANOR
Disclosed are solid state forms of Elafibranor and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
-
#75Elafibranor interrupts adipose dysfunction-mediated gut and ...
Acute elafibranor incubation inhibited ethanol-induced ASH-mice-sera-enhanced autophagy dysfunction, apoptosis, barrier disruption, and intracellular steatosis ...
-
#76GENFIT, Terns Pharmaceuticals to Commercialize Elafibranor ...
GENFIT, Terns Pharmaceuticals to Commercialize Elafibranor in China. For treatment of non-alcoholic steatohepatitis (NASH) and primary ...
-
#77Elafibranor, an Agonist of the Peroxisome Proliferator ...
Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and ...
-
#78Terns Pharmaceuticals拓臻生物與GENFIT簽署Elafibranor大 ...
拓臻將獲得elafibranor在大中華區（中國大陸、香港、澳門、臺灣）的獨家開發、註冊、和商品化權益；授權的適應症包括非酒精性肝炎（NASH）和原發性 ...
-
#79KEGG DRUG: Elafibranor - genome.jp
Nuclear receptors. Thyroid hormone like receptors. Peroxisome proliferator-activated receptor (PPAR) NR1C1 (PPARA) D11208 Elafibranor (USAN).
-
#80Clinical Pharmacy Services
Elafibranor. Obeticholic acid (OCA). Projected market entry: 2019. Mechanism of action. Dual PPAR-α/δ agonist. FXR ligand. Key clinical trial.
-
#81Elafibranor - Absource Diagnostics
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ).
-
#82Genfit scraps phase 3 trial of experimental NASH drug - PMLiVE
Genfit has put the brakes on a late-stage trial of its experimental nonalcoholic steatohepatitis (NASH) drug elafibranor after reporting ...
-
#83BRIEF-Genfit announces pivotal phase 3 clinical trial ... - Reuters
Announces pivotal phase 3 clinical trial of Elafibranor in patients with NASH following regulatory input. * Initial approval to be based on ...
-
#84File:Elafibranor.svg - Wikimedia Commons
English: Chemical structure of elafibranor (code name GFT505). Date, 31 March 2013. Source, Own work, based on (2012). "GFT-505".
-
#85Elafibranor for the Treatment of Nonalcoholic Steatohepatitis
Elafibranor is an agonist of the peroxisome proliferator–activated receptor-alpha and receptor-gamma that play key roles in fatty acid ...
-
#86Elafibranor – Medicines – SPS - Specialist Pharmacy Service
Fatty liver disease is divided into alcohol-related fatty liver disease, and non-alcoholic fatty liver disease (NAFLD).
-
#87Genfit to study elafibranor in Phase II trial for paediatric NASH
Genfit has received protocol clearance from the US FDA to conduct a Phase II trial of elafibranor in children and adolescents suffering from ...
-
#88Elafibranor | New Drug Approvals
Elafibranor (GFT505) is a dual PPARα/δ agonist that has demonstrated efficacy in disease models of nonalcoholic fatty liver disease (NAFLD)/NASH ...
-
#89罕见肝病新药！PPARα/δ激动剂elafibranor获孤儿药资格 - 生物谷
近日，该公司宣布，美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）已授予其先导候选药物PPARα/δ双重激动剂elafibranor治疗原发性胆汁性胆管 ...
-
#90Elafibranor, an Agonist of the Peroxisome Proliferator ... - Okina
Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and ...
-
#91GENFIT: Positive 36-Month DSMB Recommendation For ...
Elafibranor is currently the only late-stage, Phase 3 therapy undergoing investigation for “NASH resolution without the worsening of fibrosis”.
-
#92Elafibranor(GFT505) | 923978-27-2
Elafibranor (GFT505)에 대한 모든 정보는 Chemicalbook 에서 조회 할 수 있습니다.포함:구조식 이미지,카스 번호(CAS),분자식,녹는점,끓는 점,밀도,가격, ...
-
#93Genfit Delays Phase III Enrollment in the Race for the First ...
Genfit assured that this change won't have an impact on the launch of Elafibranor as a first-line treatment for NASH. The French biotech argues ...
-
#94Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease
Elafibranor was assessed in a multicenter international RCT (GOLDEN-505), including patients with histologic diagnosis of NASH without cirrhosis [66]. Two ...
-
#95Expected Value Investing: Analyzing Genfit's Huge Potential
Elafibranor's clinical profile is much different than other Phase 3 candidates - the drug focuses on achieving NASH resolution, rather than ...
-
#96Future Pharmacotherapy for Non-alcoholic Steatohepatitis ...
Elafibranor was tested in the phase 2b GOLDEN-505 trial (NCT01694849) which randomized 276 patients with NASH without cirrhosis to elafibranor 80 mg, ...
elafibranor 在 コバにゃんチャンネル Youtube 的最佳貼文
elafibranor 在 大象中醫 Youtube 的最佳貼文
elafibranor 在 大象中醫 Youtube 的最佳解答